T\u00fcm d\u00fcnyada, COVID19 a\u015f\u0131lar\u0131n\u0131n \u00fcretimi, di\u011fer t\u00fcm a\u015f\u0131lardan farkl\u0131 olarak onay s\u00fcre\u00e7lerinin d\u0131\u015f\u0131nda tutulmu\u015f; benzeri \u015fimdiye dek g\u00f6r\u00fclmemi\u015f bir h\u0131zda a\u015f\u0131 geli\u015ftirilmesinin yolu a\u00e7\u0131lm\u0131\u015ft\u0131r.<\/p>\n
Geli\u015ftirilen a\u015f\u0131lar<\/p>\n
T\u00fcm D\u00fcnyada 4 farkl\u0131 tipte; toplam 8 a\u015f\u0131, Faz 3 \u00e7al\u0131\u015fmalar\u0131n\u0131 tamamlayarak bir k\u0131sm\u0131 \u00fcretildikleri \u00fclkelerde, bir k\u0131sm\u0131 da D\u00fcnya Sa\u011fl\u0131 \u00d6rg\u00fct\u00fc (DS\u00d6) taraf\u0131ndan acil kullan\u0131m izni<\/em> alm\u0131\u015ft\u0131r.<\/p>\n Acil kullan\u0131m izni, bula\u015f\u0131c\u0131 hastal\u0131klar kapsam\u0131nda, halk sa\u011fl\u0131\u011f\u0131n\u0131 ciddi olarak tehdit eden istisnai durumlarda kullan\u0131lacak olan ve a\u015f\u0131n\u0131n ruhsatland\u0131r\u0131lmas\u0131 i\u00e7in gerekli veriler sa\u011flan\u0131ncaya kadar sorumlu kurum taraf\u0131ndan verilen ve s\u00fcresi belli olan ge\u00e7ici bir izindir.<\/p>\n <\/p>\n Farkl\u0131 COVID-19 a\u015f\u0131lar\u0131n\u0131n hastal\u0131\u011fa yakalanmay\u0131 ne \u00f6l\u00e7\u00fcde \u00f6nledi\u011fi veya bula\u015fmay\u0131 ne \u00f6l\u00e7\u00fcde azaltt\u0131\u011f\u0131 belirsiz olmas\u0131na kar\u015f\u0131l\u0131k, ilk elde edilen veriler a\u015f\u0131lar\u0131n, bir ki\u015finin enfekte olmas\u0131 durumunda hastal\u0131\u011f\u0131n s\u00fcresinde ve \u015fiddetinde azalma sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6stermi\u015ftir. Bu a\u015f\u0131lardan mRNA a\u015f\u0131lar\u0131 Amerika\u2019da 20.000 gebeye uygulanm\u0131\u015ft\u0131r. CDC, 19 \u015eubat 2021 itibariyle 275 tamamlanm\u0131\u015f gebelik dahil olmak \u00fczere 1.815 gebe kad\u0131n\u0131n\u0131n sonu\u00e7lar\u0131 yay\u0131nlanm\u0131\u015ft\u0131r. Gebelik s\u0131ras\u0131nda uygulanan mRNA COVID-19 (Moderna ve Pfizer BioNTech) a\u015f\u0131lar\u0131 ile ilgili gebelik \u015fekeri, gebelik zehirlenmesi, d\u00fc\u015f\u00fck do\u011fum a\u011f\u0131rl\u0131\u011f\u0131, d\u00fc\u015f\u00fck oranlar\u0131, \u00f6l\u00fc do\u011fum oranlar\u0131, erken do\u011fum ve yenido\u011fan \u00f6l\u00fcmleri y\u00f6n\u00fcnden beklenmedik bir sonu\u00e7 g\u00f6zlemlenmemi\u015ftir.<\/p>\n Gebelik s\u0131ras\u0131nda t\u00fcm a\u015f\u0131lar iste\u011fe ba\u011fl\u0131 yap\u0131lmaktad\u0131r. Ancak bilgi verirken, gebelerin COVID-19\u2019a yakalanma riskleri ve mevcut a\u015f\u0131lar\u0131n yararl\u0131 etkileri ve olas\u0131 yan etkileri hakk\u0131nda do\u011fru bilgilendirme yap\u0131lmal\u0131d\u0131r.<\/p>\n T\u00fcm d\u00fcnya ve T.C. Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131, \u00f6zellikle y\u00fcksek risk grubuna giren gebelerin COVID 19 a\u015f\u0131lar\u0131n\u0131 olmalar\u0131n\u0131 \u00f6nermektedir.<\/p>\n \u0130ngiltere, \u0130spanya, \u0130sve\u00e7, \u0130svi\u00e7re, Norve\u00e7, Finlandiya, ABD, Kanada’da gebelere COVID-19 a\u015f\u0131s\u0131 uygulan\u0131yor.<\/p>\n Avrupa \u0130la\u00e7 Ajans\u0131 (EMA) ve CDC \u00f6zel bir sa\u011fl\u0131k sorunu olmayanlarda, gebelik \u00f6ncesi, gebelik ve emzirme s\u0131ras\u0131nda COVID-19 a\u015f\u0131lar\u0131n\u0131n yap\u0131lmas\u0131n\u0131 \u00f6neriyor. CDC, gebelerin a\u015f\u0131lanmas\u0131n\u0131n hastal\u0131\u011fa ba\u011fl\u0131 komplikasyonlar ve artan ya\u015fam kay\u0131plar\u0131 nedeniyle b\u00fcy\u00fck aciliyet kazand\u0131\u011f\u0131n\u0131 duyurmu\u015ftur.<\/p>\n CDC, ABD\u2019de 153.400, \u0130ngiltere ve \u0130sko\u00e7ya\u2019da 66.000 anne aday\u0131n\u0131n COVID-19 a\u015f\u0131lar\u0131yla a\u015f\u0131land\u0131\u011f\u0131 ve ciddi bir yan etki kaydedilmedi\u011fini bildirmi\u015ftir.<\/p>\n \u0130ngiltere A\u015f\u0131lama ve Ba\u011f\u0131\u015f\u0131klama Komitesi (JCVI), gebelerde kendi ya\u015f veya risk grubundaki ki\u015filerle ayn\u0131 anda COVID-19 a\u015f\u0131lamas\u0131 \u00f6neriyor.<\/p>\n D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc (DS\u00d6) a\u015f\u0131lamadan \u00f6nce gebelik testi \u00f6nermiyor. A\u015f\u0131lama nedeniyle gebeli\u011fin ertelenmesi veya sonland\u0131r\u0131lmas\u0131 \u00f6neriliyor. DS\u00d6, emziren kad\u0131nlarda COVID-19 a\u015f\u0131s\u0131 yap\u0131lmas\u0131n\u0131 ve a\u015f\u0131lamadan sonra emzirmenin s\u00fcrd\u00fcr\u00fclmesini \u00f6nermemektedir.<\/p>\n A\u015f\u0131lanmam\u0131\u015f gebelerde istenmeyen sorunlar \u00e7ok daha y\u00fcksek olup, iki doz a\u015f\u0131lama \u00e7ok \u00f6nemlidir. Gebelik, ba\u011f\u0131\u015f\u0131kl\u0131k sistemini bask\u0131lar ve kalp-solunum sistemlerine ek y\u00fck bindirir. Bu nedenle \u00f6ncelik anneyi enfeksiyona kar\u015f\u0131 korumak olmal\u0131d\u0131r. COVID-19 a\u015f\u0131s\u0131 olman\u0131n faydalar\u0131 gebelik s\u0131ras\u0131nda a\u015f\u0131laman\u0131n olas\u0131 risklerinden \u00e7ok daha \u00f6nemlidir. A\u015f\u0131lama, yo\u011fun bak\u0131m ve erken do\u011fum dahil olmak \u00fczere hem kad\u0131nlar hem de bebekler i\u00e7in COVID-19 risklerine kar\u015f\u0131 korunman\u0131n en iyi yoludur. Nitekim COVID-19 ile ciddi \u015fekilde hastalanan gebelerin \u00e7o\u011funlu\u011fu a\u015f\u0131s\u0131zd\u0131r.<\/p>\n COVID-19 a\u015f\u0131lar\u0131na ili\u015fkin kan\u0131tlar, DS\u00d6 ile \u0130ngiltere, ABD, Kanada ve Avrupa’daki d\u00fczenleyici kurumlar taraf\u0131ndan s\u00fcrekli olarak g\u00f6zden ge\u00e7irilmektedir.<\/p>\n DS\u00d6, gebelikte a\u015f\u0131laman\u0131n faydalar\u0131n\u0131n potansiyel risklerden daha a\u011f\u0131r bast\u0131\u011f\u0131 t\u00fcm riskli durumlarda COVID-19 a\u015f\u0131lar\u0131n\u0131n kullan\u0131lmas\u0131n\u0131 \u00f6nermektedir.<\/p>\n Hamile ve emziren kad\u0131nlar, COVID-19 a\u015f\u0131lar\u0131n\u0131n ilk klinik denemelerine dahil edildi. Bu konuda izlem ve \u00e7al\u0131\u015fmalar halen s\u00fcrmektedir. Bununla birlikte mevcut COVID-19 a\u015f\u0131lar\u0131 (mRNA a\u015f\u0131lar\u0131 dahil) canl\u0131 vir\u00fcs a\u015f\u0131lar\u0131 de\u011fildir ve canl\u0131 olmayan vir\u00fcs a\u015f\u0131lar\u0131 gebelerde uzun y\u0131llard\u0131r kullan\u0131lmaktad\u0131r. COVID-19 a\u015f\u0131lar\u0131n\u0131n hayvan deneyi sonu\u00e7lar\u0131 ve uygulama sonras\u0131 takiplerden elde edilen veriler hamilelikte zararl\u0131 etkileri olmad\u0131\u011f\u0131n\u0131 g\u00f6stermi\u015ftir. Benzer \u015fekilde gebelikte a\u015f\u0131 uygulayan \u00fclke deneyimleri de a\u015f\u0131lar\u0131n gebe olmayan kad\u0131nlarla benzer etkilerinin oldu\u011funu ortaya koymu\u015ftur.<\/p>\n \u0130ngiltere\u2019de Kraliyet Kad\u0131n Hastal\u0131klar\u0131 ve Do\u011fum Uzmanlar\u0131 Koleji, COVID-19 a\u015f\u0131lar\u0131n\u0131n hamile kad\u0131nlara veya geli\u015fmekte olan bir bebe\u011fe zararl\u0131 oldu\u011fu bilinen bile\u015fenler i\u00e7ermedi\u011fini ve gebeli\u011fe etkilerine bakmak i\u00e7in hayvanlarda yap\u0131lan a\u015f\u0131 \u00e7al\u0131\u015fmalar\u0131nda a\u015f\u0131n\u0131n hamileli\u011fe veya do\u011furganl\u0131\u011fa zarar verdi\u011fine dair hi\u00e7bir kan\u0131t olmad\u0131\u011f\u0131n\u0131 bildirmi\u015ftir. mRNA COVID-19 a\u015f\u0131s\u0131n\u0131n g\u00fcvenli\u011fine ili\u015fkin erken veriler de\u011ferlendirildi\u011finde a\u015f\u0131lanm\u0131\u015f gebeler veya bebekleri i\u00e7in herhangi bir g\u00fcvenlik sorunu bildirilmemi\u015ftir. AstraZeneca ve Sinovac a\u015f\u0131lar\u0131 da giderek daha fazla \u00fclkede gebelikte kullan\u0131lmaya ba\u015flanm\u0131\u015ft\u0131r.<\/p>\n Gebeli\u011fin ilk \u00fc\u00e7 ay\u0131 d\u00fc\u015f\u00fck a\u00e7\u0131s\u0131ndan risklidir ve kad\u0131nlar\u0131n %11-16\u2019s\u0131nda g\u00f6r\u00fcl\u00fcr. Bu nedenle gebelikte ba\u011f\u0131\u015f\u0131klama baz\u0131 \u00fclkelerde 12. hafta sonras\u0131nda yap\u0131lmaktad\u0131r.<\/p>\n Bununla birlikte CDC raporuna g\u00f6re; 20 hafta \u00f6ncesi bir mRNA COVID-19 a\u015f\u0131s\u0131 olan yakla\u015f\u0131k 2.500 hamile kad\u0131n aras\u0131nda d\u00fc\u015f\u00fck yapma riskinde art\u0131\u015f bulunmam\u0131\u015ft\u0131r. ABD\u2019de a\u015f\u0131lar, gebeli\u011fin herhangi bir d\u00f6neminde uygulanmaktad\u0131r.<\/p>\n COVID-19’a kar\u015f\u0131 korumay\u0131 en \u00fcst d\u00fczeye \u00e7\u0131karmak i\u00e7in a\u015f\u0131n\u0131n m\u00fcmk\u00fcn olan en k\u0131sa s\u00fcrede yap\u0131lmas\u0131yla ilgili \u0130ngiltere\u2019de de \u00e7al\u0131\u015fmalar mevcuttur. \u0130ngiltere\u2019de Kraliyet Kad\u0131n Hastal\u0131klar\u0131 ve Do\u011fum Uzmanlar\u0131 Koleji gebe kalmaya \u00e7al\u0131\u015fan kad\u0131nlar\u0131n a\u015f\u0131lamadan sonra gebelikten ka\u00e7\u0131nmalar\u0131na gerek olmad\u0131\u011f\u0131n\u0131, a\u015f\u0131n\u0131n gebeli\u011fin her a\u015famas\u0131nda g\u00fcvenli ve etkili oldu\u011funu; a\u015f\u0131y\u0131 gebeli\u011fin ilk 12 hafta sonras\u0131na kadar ertelemenin gerekli oldu\u011funa dair bir kan\u0131t olmad\u0131\u011f\u0131n\u0131 a\u00e7\u0131klam\u0131\u015ft\u0131r. COVID-19 a\u015f\u0131lar\u0131 gebe kad\u0131nlarda daha sonraki gebeliklerinde ge\u00e7irebilecekleri a\u011f\u0131r COVID-19 hastal\u0131\u011f\u0131na kar\u015f\u0131 en iyi korumay\u0131 sa\u011flar. COVID-19 a\u015f\u0131s\u0131n\u0131n ilk dozu iyi bir koruma sa\u011flar; ancak vir\u00fcs\u00fcn delta varyant\u0131na kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k sa\u011flamak i\u00e7in en az iki doz gerekti\u011fi, gebelikte ya\u015f, kronik hastal\u0131k gibi ek riskleri olan gebelerde ikinci dozun daha \u00f6nem kazand\u0131\u011f\u0131na dikkat \u00e7ekilmektedir.<\/p>\n COVID-19 a\u015f\u0131s\u0131n\u0131n kad\u0131n ve erkeklerde do\u011furganl\u0131k sorunlar\u0131na neden oldu\u011funa, plasenta ve fet\u00fcse zarar verece\u011fine dair hi\u00e7bir kan\u0131t yoktur. Gebe kalmaya \u00e7al\u0131\u015fan kad\u0131nlar mevcut COVID-19 a\u015f\u0131lar\u0131yla a\u015f\u0131lanabilir a\u015f\u0131y\u0131 tamamlad\u0131ktan sonra da hamileli\u011fi geciktirmek i\u00e7in hi\u00e7bir neden yoktur.<\/p>\n COVID-19 a\u015f\u0131lar\u0131 yeni a\u015f\u0131lar oldu\u011fu i\u00e7in gebelikte COVID-19 a\u015f\u0131s\u0131 olan kad\u0131nlar\u0131n bebekleri \u00fczerindeki uzun vadeli etkileri hakk\u0131nda hen\u00fcz bir \u00e7al\u0131\u015fma yoktur, ancak COVID-19 a\u015f\u0131lar\u0131 \u201ccanl\u0131\u201d a\u015f\u0131lar olmad\u0131\u011f\u0131ndan, insanda enfeksiyona neden olmaz. \u00dcstelik; di\u011fer canl\u0131 olmayan a\u015f\u0131lar, gebelikte uzun y\u0131llard\u0131r g\u00fcvenle yap\u0131lmaktad\u0131r. mRNA a\u015f\u0131lar\u0131 (Pfizer ve Moderna) da enjekte edildikten sonra h\u0131zla par\u00e7alan\u0131rlar ve a\u015f\u0131lamadan sonraki birka\u00e7 g\u00fcn i\u00e7inde a\u015f\u0131 mRNA’s\u0131 kalmaz. 40.000\u2019den fazla gebe kad\u0131n\u0131n yer ald\u0131\u011f\u0131 alt\u0131 ayr\u0131 \u00e7al\u0131\u015fmada a\u015f\u0131 olman\u0131n, gebe kad\u0131nlarda d\u00fc\u015f\u00fck, erken do\u011fum, \u00f6l\u00fc do\u011fum ve bebeklerde do\u011fumsal anormallik riskini art\u0131rmad\u0131\u011f\u0131n\u0131 g\u00f6stermi\u015ftir.<\/p>\n Bu konuda yeterli say\u0131da ara\u015ft\u0131rma bulunmamaktad\u0131r. Sadece bir gebede a\u015f\u0131 sonras\u0131 koruyucu antikorlar\u0131n plasentay\u0131 ge\u00e7erek bebe\u011fin COVID-19’a kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131\u011f\u0131na yard\u0131mc\u0131 oldu\u011fu g\u00f6sterilmi\u015ftir. Annenin a\u015f\u0131lanmas\u0131n\u0131n yeni do\u011fanlar\u0131 COVID-19’dan korumaya yard\u0131mc\u0131 olmas\u0131 muhtemel olsa da bu antikorlar\u0131n ne kadar koruma sa\u011flayaca\u011f\u0131n\u0131 veya bu koruman\u0131n ne kadar s\u00fcrece\u011fini belirlemek i\u00e7in daha fazla ara\u015ft\u0131rmaya ihtiya\u00e7 vard\u0131r.<\/p>\n COVID-19 a\u015f\u0131lar\u0131 canl\u0131 vir\u00fcs i\u00e7ermedi\u011finden bebek i\u00e7in risk olu\u015fturmas\u0131 beklenmez. COVID-19 a\u015f\u0131s\u0131 gebeler ve bebekler dahil olmak \u00fczere hi\u00e7 kimseyi COVID-19 ile hasta edemez, a\u015f\u0131lar v\u00fccutta \u00e7o\u011falabilen canl\u0131 organizmalar i\u00e7ermedi\u011finden anne karn\u0131ndaki bebe\u011fe bula\u015famaz. Erken veriler gebelik s\u0131ras\u0131nda bir mRNA COVID-19 a\u015f\u0131s\u0131 olman\u0131n enfeksiyon riskini azaltt\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. Koronavir\u00fcs a\u015f\u0131s\u0131 olduysan\u0131z emzirmeyi ertelemenize veya kesmenize gerek yoktur.<\/p>\n Evet, t\u00fcp bebek tedavisi s\u0131ras\u0131nda COVID-19 a\u015f\u0131s\u0131 yapt\u0131rabilirsiniz. Bu s\u00fcre\u00e7te a\u015f\u0131 yapt\u0131r\u0131rsan\u0131z, kendinizi ve bebe\u011finizi gebelikte COVID-19 enfeksiyonunun etkilerinden korumaya yard\u0131mc\u0131 olabilirsiniz.<\/p>\n Gebelerde a\u015f\u0131lamadan sonra gebe olmayanlardan farkl\u0131 yan etkiler bildirilmemi\u015ftir. Genel olarak a\u015f\u0131lar\u0131n yan etkileri hafiftir ve uzun s\u00fcrmez. A\u015f\u0131dan sonraki ilk iki g\u00fcnde en \u00e7ok g\u00f6r\u00fclen yan etkiler; yorgunluk, a\u011fr\u0131, titreme ve enjeksiyon yap\u0131lan kolda a\u011fr\u0131 veya hassasiyettir. Gebe olmayan bireylerde COVID-19 a\u015f\u0131lar\u0131n\u0131n bir veya iki g\u00fcn s\u00fcren ate\u015f veya kas a\u011fr\u0131s\u0131 gibi hafif ve k\u0131sa s\u00fcreli yan etkileri oldu\u011fu bilinmektedir. Alerjik reaksiyon veya p\u0131ht\u0131la\u015fma sorunlar\u0131 gibi ciddi yan etkiler \u00e7ok nadirdir. Ayr\u0131ca grip benzeri belirtiler olabilir. Ate\u015finiz 38\u00b0C veya \u00fczerine y\u00fckselirse dinlenip, hamilelikte g\u00fcvenli olan parasetamol kullanabilirsiniz.<\/p>\n","protected":false},"excerpt":{"rendered":" T\u00fcm d\u00fcnyada, COVID19 a\u015f\u0131lar\u0131n\u0131n \u00fcretimi, di\u011fer t\u00fcm a\u015f\u0131lardan farkl\u0131 olarak onay s\u00fcre\u00e7lerinin d\u0131\u015f\u0131nda tutulmu\u015f; benzeri \u015fimdiye dek g\u00f6r\u00fclmemi\u015f bir h\u0131zda a\u015f\u0131 geli\u015ftirilmesinin yolu a\u00e7\u0131lm\u0131\u015ft\u0131r. Geli\u015ftirilen a\u015f\u0131lar mRNA a\u015f\u0131lar\u0131 \u0130naktif a\u015f\u0131lar Rekombinant alt \u00fcnite a\u015f\u0131lar\u0131 Adenovirus vekt\u00f6r a\u015f\u0131lar\u0131 T\u00fcm D\u00fcnyada 4 farkl\u0131 tipte; toplam 8 a\u015f\u0131, Faz 3 \u00e7al\u0131\u015fmalar\u0131n\u0131 tamamlayarak bir k\u0131sm\u0131 \u00fcretildikleri \u00fclkelerde, bir k\u0131sm\u0131 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[30],"tags":[1135,1133,1132,1134,1136],"yoast_head":"\n\n
\nhidroksit adjuvanlar\u0131, veri eksikli\u011finden dolay\u0131, belirlenmi\u015f bir FDA g\u00fcvenlik kategorisine sahip olmasa da, inaktive vir\u00fcs a\u015f\u0131lar\u0131 hamilelikte g\u00fcvenli kabul edilir. Adjuvan olarak aluminyum tuzlar\u0131, hepatit B, TDaP (tetanoz, difteri ve bo\u011fmaca) ve insan papilloma vir\u00fcs\u00fc (HPV) dahil olmak \u00fczere bir\u00e7ok a\u015f\u0131da kullan\u0131lmaktad\u0131r. Risk fakt\u00f6r\u00fc ta\u015f\u0131yan gebelere \u00f6nerilir.<\/li>\n\n
\n
Gebeysem, gebe kalmay\u0131 planl\u0131yorsam veya emziriyorsam COVID-19 a\u015f\u0131s\u0131 olabilir miyim?<\/h4>\n
COVID-19 a\u015f\u0131lar\u0131 gebe kad\u0131nlar i\u00e7in g\u00fcvenli ve etkili midir?<\/h4>\n
Gebelikte ne zaman a\u015f\u0131 yapt\u0131rmal\u0131y\u0131m?<\/h4>\n
COVID-19 a\u015f\u0131s\u0131 do\u011furganl\u0131\u011f\u0131m\u0131 etkiler mi?<\/h4>\n
COVID-19 a\u015f\u0131s\u0131n\u0131n gebe iken a\u015f\u0131lanm\u0131\u015f kad\u0131nlar\u0131n bebekleri \u00fczerindeki etkisi hakk\u0131nda ne biliniyor?<\/h4>\n
A\u015f\u0131lar, do\u011fmam\u0131\u015f \u00e7ocu\u011funuza COVID-19’a kar\u015f\u0131 bir miktar koruma sa\u011flayabilir mi?<\/h4>\n
Emzirirken COVID-19 a\u015f\u0131s\u0131 olabilir miyim?<\/h4>\n
T\u00fcp bebek tedavisi s\u00fcrecinde a\u015f\u0131 yapt\u0131rabilir miyim?<\/h4>\n
COVID-19 a\u015f\u0131lar\u0131n\u0131n yan etkileri nelerdir ve a\u015f\u0131ya kar\u015f\u0131 bir reaksiyon geli\u015firse ne yapmal\u0131d\u0131r?<\/h4>\n